Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Wheatley

Showing results (1-10 of 145) with videos related to

Pageof 15
Sort By:
British Journal of Haematology|July 26, 2002
Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--a statistician's viewKeith Wheatley
British Journal of Haematology|July 26, 2002
SAB--a promising new treatment to improve remission rates in AML in the elderly?Keith Wheatley
Lancet (London, England)|October 25, 2003
ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefitKeith Wheatley, Richard Gray
Controlled Clinical Trials|February 1, 2003
Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomizationKeith Wheatley, David Clayton
International Journal of Epidemiology|April 13, 2004
Commentary: Mendelian randomization--an update on its use to evaluate allogeneic stem cell transplantation in leukaemiaKeith Wheatley, Richard Gray
Cancer Treatment Reviews|February 10, 2004
High-dose chemotherapy and stem cell transplantation does not improve relapse-free or overall survival in women with high-risk breast cancerRobert W Carlson, Keith Wheatley
Lancet (London, England)|May 4, 2002
Priority-setting decisions for new cancer drugsKeith Wheatley, Benjamin Djulbegovic, Axel Glasmacher
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2007
Does adjuvant vaccine therapy really have activity in malignant melanoma?Keith Wheatley, Natalie J Ives, Paul Lorigan
Journal of Evidence-Based Medicine|February 26, 2011
Balancing treatment allocations by clinician or center in randomized trials allows unacceptable levels of treatment predictionRobert K Hills, Richard Gray, Keith Wheatley
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2006
Problems with up-front randomization in clinical trialsKeith Wheatley, Robert K Hills, Alan K Burnett
Pageof 15

Showing results (1-10 of 145) with videos related to

Sort By:
Pageof 15
British Journal of Haematology|July 26, 2002
Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--a statistician's viewKeith Wheatley
British Journal of Haematology|July 26, 2002
SAB--a promising new treatment to improve remission rates in AML in the elderly?Keith Wheatley
Lancet (London, England)|October 25, 2003
ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefitKeith Wheatley, Richard Gray
Controlled Clinical Trials|February 1, 2003
Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomizationKeith Wheatley, David Clayton
International Journal of Epidemiology|April 13, 2004
Commentary: Mendelian randomization--an update on its use to evaluate allogeneic stem cell transplantation in leukaemiaKeith Wheatley, Richard Gray
Cancer Treatment Reviews|February 10, 2004
High-dose chemotherapy and stem cell transplantation does not improve relapse-free or overall survival in women with high-risk breast cancerRobert W Carlson, Keith Wheatley
Lancet (London, England)|May 4, 2002
Priority-setting decisions for new cancer drugsKeith Wheatley, Benjamin Djulbegovic, Axel Glasmacher
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2007
Does adjuvant vaccine therapy really have activity in malignant melanoma?Keith Wheatley, Natalie J Ives, Paul Lorigan
Journal of Evidence-Based Medicine|February 26, 2011
Balancing treatment allocations by clinician or center in randomized trials allows unacceptable levels of treatment predictionRobert K Hills, Richard Gray, Keith Wheatley
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2006
Problems with up-front randomization in clinical trialsKeith Wheatley, Robert K Hills, Alan K Burnett
Pageof 15